Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Ipilimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 221 Carcinoma, Non-Small-Cell Lung 70 Carcinoma, Renal Cell 55 Neoplasm Metastasis 45 Neoplasms 40 Prostatic Neoplasms 32 Lung Neoplasms 27 Uveal Melanoma 25 Pancreatic Neoplasms 23 Carcinoma, Hepatocellular 23 Colorectal Neoplasms 22 Brain Neoplasms 21 Sarcoma 20 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 17 Small Cell Lung Carcinoma 17 Kidney Neoplasms 17 Skin Neoplasms 16 Carcinoma, Transitional Cell 15 Ovarian Neoplasms 14 Diabetes Mellitus, Insulin-Dependent, 12 14 Urinary Bladder Neoplasms 13 Uterine Cervical Neoplasms 12 Triple Negative Breast Neoplasms 12 Mesothelioma 11 Stomach Neoplasms 10 Recurrence 10 Multiple Myeloma 10 Head and Neck Neoplasms 10 Glioblastoma 10

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡